The overt hepatic encephalopathy market is undergoing substantial change, fueled by rising liver disease prevalence, advances in treatment options, and a growing focus on patient quality of life. overt hepatic encephalopathy, a serious neurological complication of liver dysfunction, impacts patients’ cognitive function and overall well-being, creating a strong demand for effective therapeutic interventions. Here’s a closer look at the top drivers influencing the overt hepatic encephalopathy market in 2024.

According to Stratview Research, the overt hepatic encephalopathy market was estimated at USD 87.8 million in 2022 and is likely to grow at a CAGR of 10.67% during 2023-2028 to reach USD 161.73 million in 2028.

1. Increasing Prevalence of Liver Disease

One of the primary drivers behind the growth of the overt hepatic encephalopathy market is the rising global prevalence of liver-related conditions such as cirrhosis, hepatitis, and non-alcoholic fatty liver disease (NAFLD). Factors such as alcohol consumption, poor diet, and metabolic syndrome have contributed to the increased incidence of chronic liver disease worldwide. Regions such as North America and Europe, where obesity and alcohol-related liver issues are more common, are seeing particularly high demand for overt hepatic encephalopathy treatments. As these conditions progress, patients are at higher risk of developing overt hepatic encephalopathy, making targeted therapies essential.

2. Advances in OHE Treatment Options

Significant advancements in therapeutic approaches for overt hepatic encephalopathy are enhancing the quality of care. Traditional treatments, such as lactulose and rifaximin, aim to reduce ammonia levels in the brain but have limitations in terms of efficacy and tolerability. Newer treatment approaches are focusing on targeting the gut microbiome, enhancing ammonia metabolism, and developing drugs with fewer side effects. Companies are investing heavily in research and development, looking to create therapies that offer improved outcomes and potentially prevent recurrence, which is a key challenge for current treatment regimens.

3. Emphasis on Early Diagnosis and Preventative Care

Healthcare providers and policymakers are increasingly focusing on early diagnosis and preventative care for overt hepatic encephalopathy to reduce hospitalizations and healthcare costs. Preventative strategies involve the use of maintenance therapies to lower the risk of overt hepatic encephalopathy recurrence, which can result in fewer severe episodes and hospital stays. This approach also helps improve the quality of life for patients, as it reduces the impact of recurring symptoms. Consequently, there is growing demand for maintenance therapies, which is expected to boost market growth significantly.

4. Rising Awareness and Access in Emerging Markets

In emerging markets, increasing awareness of liver disease complications is contributing to the demand for overt hepatic encephalopathy treatments. Improved healthcare infrastructure and increased investment in liver disease education and diagnosis are driving growth in regions such as Asia-Pacific and Latin America. As more patients gain access to healthcare services, the demand for overt hepatic encephalopathy therapies is expected to expand, making these regions attractive for market growth.

Conclusion

In 2024, the overt hepatic encephalopathy market is set to grow as liver disease prevalence rises and treatment innovations improve outcomes. With a greater focus on early intervention and preventative care, as well as increasing awareness in emerging regions, the overt hepatic encephalopathy market is well-positioned for significant expansion. These drivers are not only shaping the industry but also promise better care for patients facing the challenges of hepatic encephalopathy.